Even when carrying the ‘high-risk’ NOD2 variant, with an average life-time risk for IBD of 1.3%, this represents an increase of lifetime risk to 3.9% (life-time risk 1.3% multiplied with the effect size of 3.0) (Table 1). This evidence concerns the gene NOD2 and inflammatory bowel disease.